Seres Therapeutics, Inc. (MCRB) News
Filter MCRB News Items
MCRB News Results
|Loading, please wait...|
MCRB News Highlights
- MCRB's 30 day story count now stands at 4.
- Over the past 19 days, the trend for MCRB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MCRB are III and LOAN.
Latest MCRB News From Around the Web
Below are the latest news stories about Seres Therapeutics Inc that investors may wish to consider to help them evaluate MCRB as an investment opportunity.
In this article, we discuss Cathie Wood’s top 15 small-cap stock picks. If you want to skip our detailed analysis of Wood’s history, investment philosophy, and hedge fund performance, go directly to Cathie Wood’s Top 5 Small-Cap Stock Picks. Catherine Wood is an American millionaire investor, who founded ARK Investment Management in 2014. She serves […]
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
CAMBRIDGE, Mass., October 02, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). SER-109 was associated with significantly greater reduction of antimicrobial resistance genes (ARGs) compared to placebo, with the reduction observed both rapidly (by Week 1) and sustained through W
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
CAMBRIDGE, Mass., September 29, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI), will be presented at the IDWeek 2021 Virtual Conference (Sept. 29-Oct. 3). The Company will be presenting seven posters and oral presentations related to SER-109 and C. difficile, including a late-breaker, as well
Human Microbiome Market Skyrocketing Revenue Growth of US$ 2,921.68 million by 2028 with Profiling Companies- MaaT Pharma, Eligo Bioscience Merck & Co. Inc, AOBiome LLC, Kaleido, Seres Therapeutics
The Human Microbiome Market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 20212028. The human microbiota consists of the trillions of symbiotic microbial
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV open-label study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). The target enrollment of a minimum of 300 subjects for the SER-109 safety database was reached in conjunction with a prior completed Phase 3 study, ECOSPOR lll. Seres is re
The company completed its target enrollment in a pivotal clinical study.
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bicycle Therapeutics plc (NASDAQ: BCYC ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) DexCom, Inc. (NASDAQ: DXCM ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Medtronic plc (NYSE: MDT ) MiMedx Group, Inc. (NASDAQ: MDXG ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) Quest Diagnostics Incorporated (NYSE: DGX ) (raised its full-year guidance) ResMed Inc. (NYSE: RMD ) Stryker Corporation (NYSE: SYK ) Tango Therapeutics, Inc. (N...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in three upcoming investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference: Seres will participate in a pre-recorded fireside chat that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET. Morgan Stanley 19th Annual Global Healthcare Conference: Seres will participate in a fireside chat on W
No summary available.